Clinical trial Recruiting at 2 sites Observational

Creating a questionnaire to assess abdominal issues in cystic fibrosis patients

Official title: Evaluation and Validation of a New Questionnaire to Identify and Quantify Abdominal Symptoms in Patients With Cystic Fibrosis Following FDA Guidelines: the CF Abd-Score (Primarily Named JenAbdomen-CF Score)

Run by Medizinische Hochschule Brandenburg Theodor Fontane · NCT03052283 · Data updated 2026-11-12

This study is trying to create a new questionnaire to help cystic fibrosis patients report their abdominal issues so that doctors can better understand and treat them.

More Cystic Fibrosis trials

Quick facts

Study typeObservational
SexAll
Enrollment2000 (estimated)
SponsorMedizinische Hochschule Brandenburg Theodor Fontane
Academic / other
Locations2 sites (Brandenburg an der Havel and 1 other locations)
StatusRecruiting
StartedJanuary 26, 2017
Main results expectedDecember 31, 2026
Study endsDecember 31, 2027
Registry record updatedApril 4, 2023
Trial IDNCT03052283 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals diagnosed with cystic fibrosis and age-matched healthy controls.

Probably not a fit

Patients with other diseases causing abdominal symptoms, such as inflammatory bowel disease or celiac disease, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on developing and validating a new patient-reported outcome measure (PROM) specifically designed to assess abdominal involvement in individuals with cystic fibrosis (CF). The CFAbd-Score will be created through a collaborative process involving CF patients, their families, and healthcare professionals. The study will evaluate the reliability, reproducibility, and responsiveness of the questionnaire, as well as its applicability across different age groups and CF centers. Additionally, the study aims to adapt the CFAbd-Score for use in various countries and languages.

Why it matters

Potential benefit: If successful, this study could provide a standardized tool for better monitoring and management of abdominal symptoms in cystic fibrosis patients.

How similar studies have gone: Other studies have successfully developed disease-specific PROMs, indicating a promising approach for this novel tool.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

CF cohort:

Diagnosis of CF determined by

* a sweat chloride of \>60 mEq/L and/or
* detection of 2 disease causing CFTR mutations with evidence of organ involvement.

Healthy controls:

* Age-matched

Exclusion Criteria:

CF cohort:

* Lacking ability to cooperate of patients /their families, respectively

Healthy controls:

* Other diseases causing abdominal symptoms (Inflammatory bowel disease (IBD), alpha 1 antitrypsin deficiency, celiac disease, food allergy, gastroenteritis, etc.)

Where it's running

  • Klinikum Westbrandenburg
    Brandenburg an der Havel, Germany
    Recruiting
  • Medizinische Hochschule Brandenburg (MHB), University
    Brandenburg an der Havel, Germany
    Recruiting

Study contacts

  • Principal investigator: Jochen G Mainz, Prof. MD — Medizinische Hochschule Brandenburg (MHB), University
  • Study coordinator: Jochen G Mainz, Prof. MD
  • Email: jochen.mainz@mhb-fontane.de
  • Phone: +493381411803

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.